Ensysce Biosciences announced that the PF614-201 study, ‘A Randomized, Double-Blind, Placebo-Controlled Crossover Study of PF614 on Analgesic Response in the Cold Pressor Test in Healthy Male Subjects’ has completed enrollment. The goal of this exploratory Phase 2 PF614-201 study is to confirm the approximate time of onset for PF614 analgesic effects prior to initiation of Phase 3 efficacy evaluations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENSC:
- Ensysce Biosciences files to sell 6.18M shares of common stock for holders
- Ensysce Biosciences secures $1.7M convertible note financing
- Ensysce Biosciences secures $1.7M convertible senior note financing
- Ensysce Biosciences completes site initiation visit for PF614-201 study
- Ensysce Biosciences price target lowered to $7 from $9 at H.C. Wainwright
